Ποια είναι η τιμή για HLS Therapeutics Inc. (HLS)

Η τιμή για HLS Therapeutics Inc. (HLS) είναι $2.75

Ποια είναι η κεφαλαιοποίηση αγοράς για HLS Therapeutics Inc. (HLS)

Η κεφαλαιοποίηση αγοράς για HLS Therapeutics Inc. (HLS) είναι $86.08M

HLS Therapeutics Inc. (HLS) Τιμή και Κεφαλαιοποίηση Αγοράς

HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.

Η τιμή για HLS	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$166,632 $86.08M	NVDA	$5.211T	+6,054,252.44%
$145,381 $86.08M	AAPL	$4.547T	+5,282,121.09%
$133,094 $86.08M	GOOG	$4.162T	+4,835,692.10%
$114,878 $86.08M	MSFT	$3.593T	+4,173,855.39%
$89,300.55 $86.08M	AMZN	$2.793T	+3,244,522.42%

Η τιμή για HLS

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$166,632 $86.08M